Provided by Tiger Trade Technology Pte. Ltd.

Q/C TECHNOLOGIES INC,

2.58
-0.1500-5.49%
Post-market: 2.630.0485+1.88%19:22 EDT
Volume:182.48K
Turnover:488.32K
Market Cap:21.13M
PE:-0.54
High:2.83
Open:2.72
Low:2.57
Close:2.73
52wk High:9.31
52wk Low:2.50
Shares:8.19M
Float Shares:8.11M
Volume Ratio:1.46
T/O Rate:2.25%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.7464
EPS(LYR):-8.6618
ROE:-108.00%
ROA:-33.44%
PB:1.33
PE(LYR):-0.30

Loading ...

Company Profile

Company Name:
Q/C TECHNOLOGIES INC,
Exchange:
NASDAQ
Establishment Date:
2014
Employees:
3
Office Location:
1185 Avenue of the Americas,Suite 249,New York,New York,United States
Zip Code:
10036
Fax:
- -
Introduction:
TNF Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to treat diseases and disorders marked by acute or chronic inflammation. The company's second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. The Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve the growing CBD market, which includes FDA approved drugs and CBD products not regulated as drugs. TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. and changed its name to TNF Pharmaceuticals, Inc. in July 2024. The company was founded in 2014 and is headquartered in Baltimore, Maryland.

Directors

Name
Position
Joshua N. Silverman
Director and Executive Chairman
Bill J. White
Independent Director
Bruce Bernstein
Independent Director
Christopher C. Schreiber
Independent Director
Mitchell Glass
Chief Medical Officer and Director
Stephen Friscia
Independent Director
Chelsea Voss
Director

Shareholders

Name
Position
Ian Rhodes
Interim Chief Financial Officer
Joshua N. Silverman
Director and Executive Chairman
Mitchell Glass
Chief Medical Officer and Director